Lewellen O R, Templeton R
Scand J Rheumatol Suppl. 1976;1976(0):53-62.
The pharmacokinetics of ketoprofen were studied in 5 healthy male volunteers after the oral administration of Orudis as a single dose (50 mg) and during, and after a 24-day repeated dosing regimen (50 mg q.i.d.). Levels of ketoprofen in plasma and urine and of conjugated ketoprofen in urine were measured after extraction, by a gas-liquid chromatographic method, which involved the use of a structurally similar internal standard. The minimum level of detection of the method was 40 ng ketoprofen/ml of plasma or 20 ng ketoprofen/ml of urine. The pharmacokinetic parameters obtained following a single oral dose, were comparable with those obtained in previous studies with human subjects from Britain, America and France. Repeated oral administration of a therapeutically effective dose of Orudis (50 mg q.i.d.), resulted in the rapid attainment of a plateau plasma level of ketoprofen, which was maintained throughout the course of dosing. Ketoprofen plasma levels and urinary clearance after the final dose of the 24-day repeated oral dosing regimen, were more variable and generally lower than those found following a single oral dose. However, the early plasma half-lives for the two experiments were similar. It was concluded that in the initial stages of repeated dosing a reduction in ketoprofen absorption, compared to that found after a single oral dose, occurred, and resulted in lower plasma levels of drug.
在5名健康男性志愿者中研究了酮洛芬的药代动力学。单次口服奥鲁地(Orudis)(50毫克)后,以及在24天重复给药方案(每日4次,每次50毫克)期间和之后进行了研究。通过气液色谱法测定血浆和尿液中酮洛芬的水平以及尿液中结合酮洛芬的水平,该方法使用了结构相似的内标。该方法的最低检测限为血浆中40纳克酮洛芬/毫升或尿液中20纳克酮洛芬/毫升。单次口服给药后获得的药代动力学参数与之前在英国、美国和法国的人体研究中获得的参数相当。重复口服治疗有效剂量的奥鲁地(每日4次,每次50毫克)导致酮洛芬的血浆水平迅速达到稳定状态,并在整个给药过程中维持。24天重复口服给药方案最后一剂后的酮洛芬血浆水平和尿清除率变化更大,且通常低于单次口服给药后的水平。然而,两个实验的早期血浆半衰期相似。得出的结论是,在重复给药的初始阶段,与单次口服给药后相比,酮洛芬的吸收减少,导致药物血浆水平降低。